[The serum concentration of interleukin-2 in a hemodialysis patient--report from interleukin adjuvant therapy for local recurrent renal cancer].
We started interleukin-2 (IL-2) adjuvant therapy after resection of a repeated local recurrence of renal cell carcinoma in a hemodialysis patient. It is reported that IL-2 is mainly metabolized in proximal tubules of the kidney. To determine the IL-2 concentration, we employed the ELISA method using anti-human IL-2 antibodies. At the concentration of 350,000 Japan reference unit (JRU) in a hemodialysis patient, the change in serum IL-2 was almost the same speed compared to 700,000 JRU in normal renal function patients, which was reported previously. This report may also be a good tool to define the ideal dose of IL-2 in hemodialysis patients.